keynote-716: adjuvant pembrolizumab for high-risk melanoma
Published 3 years ago • 109 plays • Length 0:43Download video MP4
Download video MP3
Similar videos
-
5:54
keynote-716: adjuvant therapy with pembrolizumab for patients with high-risk stage ii melanoma
-
3:39
keynote-716: pembrolizumab for patients with high-risk stage ii melanoma
-
1:08
keynote-716: safety profile and results of pembrolizumab for melanoma
-
1:36
results from keynote-716: adjuvant therapy with pembrolizumab in high-risk stage ii melanoma
-
2:18
keynote-716: longer follow up supports pembrolizumab use in stage iib/iic melanoma
-
1:30
adjuvant therapy for high-risk melanoma
-
0:33
keynote-716: pembrolizumab in stage 2b/2c cutaneous melanoma
-
0:48
final analysis of distant metastasis-free survival in the keynote-716 study
-
7:34
adjuvant therapy for melanoma: nivolumab, pembrolizumab, ipilimumab, dabrafenib and trametinib
-
5:01
melanoma highlights from esmo 2021
-
5:17
pembrolizumab as adjuvant treatment for high risk melanoma
-
2:17
melanoma highlights from esmo 2021
-
1:11
highlights for skin cancer at esmo 2021
-
0:39
pembrolizumab, emavusterib radiosurgery: a novel trimodal therapy for metastatic melanoma
-
1:14
adjuvant and neoadjuvant clinical trials for melanoma
-
7:19
keynote-555: pembrolizumab bioavailability after subcutaneous administration in melanoma
-
0:50
emerging role of adjuvant immunotherapy in oncology
-
1:22
dr. weber on adjuvant pembrolizumab in melanoma
-
1:34
dr. eggermont on responses to adjuvant pembrolizumab in stage iii melanoma subtypes